LRRK2 and Parkinson disease: A second target of PD that has garnered significant attention in the development of novel neurotherapeutics is the large, multidomain Roco protein leucine-rich repeat kinase 2 (LRRK2), which as the name suggests, contains a signature leucine-rich repeat domain (144).